Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0
|
作者：
Zeidan, Amer M. [1 ,2 ]
Savona, Michael R. [3 ]
Madanat, Yazan F. [4 ]
Fenaux, Pierre [5 ]
Komrokji, Rami S. [6 ]
Jonasova, Anna [7 ]
Illmer, Thomas
Sun, Libo [8 ]
Berry, Tymara [8 ]
Feller, Faye M. [8 ]
Navada, Shyamala [8 ]
Santini, Valeria [9 ,10 ]
Platzbecker, Uwe [11 ]
机构：
[1] Yale Univ, Yale Sch Med, New Haven, CT USA
[2] Yale Univ, Yale Canc Ctr, New Haven, CT USA
[3] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[5] Univ Paris 07, Hop St Louis, Paris, France
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Gen Hosp, Prague, Czech Republic
[8] Geron Corp, Parsippany, NJ USA
[9] Azienda Osped Univ Careggi, MDS UNIT, DMSC, Florence, Italy
[10] Univ Florence, Florence, Italy
[11] Leipzig Univ Hosp, Cellular Therapy & Hemostaseol, Leipzig, Germany
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180962
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
    Hoeks, Marlijn
    Yu, Ge
    Langemeijer, Saskia
    Crouch, Simon
    de Swart, Louise
    Fenaux, Pierre
    Symeonidis, Argiris
    Cermak, Jaroslav
    Hellstrom-Lindberg, Eva
    Sanz, Guillermo
    Stauder, Reinhard
    Holm, Mette Skov
    Mittelman, Moshe
    Madry, Krzysztof
    Malcovati, Luca
    Tatic, Aurelia
    Almeida, Antonio Medina
    Germing, Ulrich
    Savic, Aleksandar
    Simec, Njetocka Gredelj
    Culligan, Dominic
    Itzykson, Raphael
    Guerci-Bresler, Agnes
    Slama, Borhane
    van de Loosdrecht, Arjan
    van Marrewijk, Corine
    Droste, Jackie
    Blijlevens, Nicole
    van Kraaij, Marian
    Bowen, David
    de Witte, Theo
    Smith, Alex
    HAEMATOLOGICA, 2020, 105 (03) : 640 - 651
  • [42] Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study
    Platzbecker, Uwe
    Santini, Valeria
    Komrokji, Rami S.
    Zeidan, Amer M.
    Garcia-Manero, Guillermo
    Buckstein, Rena J.
    Rose, Shelonitda
    Fabre, Shannon
    Miteva, Dimana
    Zhang, Jennie
    Yucel, Aylin
    Hughes, Christina
    Fenaux, Pierre
    BLOOD, 2021, 138
  • [43] Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study
    Mittelman, Moshe
    Henry, David H.
    Glaspy, John
    Tombak, Anil
    Harrup, Rosemary Anne
    Madry, Krzysztof
    Grabowska, Barbara
    Platzbecker, Uwe
    Lee, Tyson
    Modelska, Katharina
    BLOOD, 2023, 142
  • [44] Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).
    Sekeres, Mikkael A.
    Giagounidis, Aristoteles
    Kantarjian, Hagop M.
    Mufti, Ghulam J.
    Fenaux, Pierre
    Jia, Catherine
    Yang, Allen S.
    Platzbecker, Uwe
    BLOOD, 2012, 120 (21)
  • [45] Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study
    Platzbecker, Uwe
    Kiewe, Philipp
    Germing, Ulrich
    Gotze, Katharina S.
    Mayer, Karin
    Radsak, Markus P.
    Wolff, Thomas
    Chromik, Joerg
    Wilson, Dawn
    Zhang, Xiaosha
    Rovaldi, Chris
    Laadem, Abderrahmane
    Sherman, Matthew Leigh
    Attie, Kenneth Morris
    Reynolds, Joseph
    Linde, Peter Guest
    Giagounidis, Aristoteles
    BLOOD, 2017, 130
  • [46] Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
    Gerds, Aaron T.
    Gupta, Shaloo
    Binder, Gary
    Sekeres, Mikkael A.
    Nazha, Aziz
    Carraway, Hetty E.
    Hawthorne, Stephanie
    King-Concialdi, Kristen
    McGuire, Michael
    BLOOD, 2016, 128 (22)
  • [47] Treatment Patterns and Transfusion Outcomes Among Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in Routine Clinical Practice in the United States (US)
    Mukherjee, Sudipto
    Brown-Bickerstaff, Cherrishe
    Huggar, David
    Falkenstein, Angelica
    Makinde, Adeola Y.
    Bland, Emily
    Laney, JaLyna
    Garretson, Marne
    McBride, Ali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S352 - S353
  • [48] Luspatercept Versus Epoetin Alfa for Treatment (Tx) of Anemia in Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients (pts) Requiring RBC Transfusions (RBCT): Data from the Phase 3 COMMANDS Study
    Platzbecker, U.
    Della Porta, M. G.
    Santini, V.
    Zeidan, A. M.
    Fenaux, P.
    Komrokji, R. S.
    Shortt, J.
    Valcarcel, D.
    Jonasova, A.
    Dimicoli-Salazar, S.
    Tiong, I. S.
    Lin, C. -C.
    Li, J.
    Zhang, J.
    Giuseppi, A. C.
    Kreitz, S.
    Pozharskaya, V.
    Keeperman, K. L.
    Rose, S.
    Shetty, J. K.
    Hayati, S.
    Vodala, S.
    Degulys, A.
    Paolini, S.
    Cluzeau, T.
    Garcia-Manero, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 16 - 17
  • [49] A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
    U Platzbecker
    A Symeonidis
    E N Oliva
    J S Goede
    M Delforge
    J Mayer
    B Slama
    S Badre
    E Gasal
    B Mehta
    J Franklin
    Leukemia, 2017, 31 : 1944 - 1950
  • [50] Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS)
    Coughlan, Anna
    Klijn, Sven L.
    Xiao, Hong
    White, Benjamin
    Litkiewicz, Michal
    Kadambi, Ananth
    Sichevaya, Alina
    Hnoosh, Ahmed
    Miteva, Dimana
    Yucel, Aylin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S351 - S351
12345